Illustrative case: A boy’s voice deepens and his growth accelerates during a short course of testosterone. Has puberty started? Not necessarily: those changes show that his tissues responded to androgen, but they do not prove that his own hypothalamic-pituitary-gonadal axis has activated.
At follow-up, he is 15, and his testicular volume remains about 2 mL after testosterone. At age 13, 2 mL alone had not yet met the usual age-based definition of delayed puberty—lack of testicular enlargement to at least 4 mL by age 14. At 15, persistent prepubertal testes merit structured reassessment. The key question is not simply whether the medication “worked,” but whether endogenous puberty is progressing.
Separate androgen effects from axis activation
Testosterone can produce androgen-dependent changes without stimulating the full sequence of central puberty. In boys, progressive testicular enlargement is the more useful clinical evidence of gonadotropin activity and endogenous pubertal progression.
| Finding after testosterone | What it can—and cannot—show |
|---|---|
| Voice change, penile growth, pubic hair, or faster linear growth | Consistent with androgen exposure; does not by itself establish endogenous puberty. |
| Higher testosterone measured soon after an injection | May reflect the prescribed medication. Timing and formulation matter when interpreting results. |
| Increasing testicular volume on serial examinations after treatment | Supports activation of the boy’s own pubertal axis, especially when accompanied by other progressive changes. |
Testicular growth depends on gonadotropin-driven testicular development; circulating testosterone from an injection can virilize the boy without producing that same signal. A small clinical study of seven boys found no increase in testicular length during a four-month testosterone course, but growth over the next four months. That observation illustrates why follow-up matters; it is not a universal timetable or a diagnostic cutoff.
Use the right clues at follow-up
First, establish the timeline. Review the original and current testicular-volume measurements, how they were assessed, the exact treatment and last-dose date, and whether any changes continued after treatment stopped. A single measurement may be imprecise; a consistent trend is more informative.
Then revisit the broader growth and developmental history. In this case, a father who matured late and a previously steady prepubertal growth velocity support self-limited delay, but neither proves it. Review the actual bone-age report rather than assuming it is delayed. Check current height and weight trajectories, nutrition, intensive exercise, chronic illness, and medications that could affect growth or pubertal timing.
Ask about clues to less common but important causes. A history of micropenis or undescended testes, prior chemotherapy or testicular injury, or signs of other pituitary hormone problems changes the differential. Headache or visual symptoms warrant particular attention. Normal smell and no midline findings make some syndromic clues less apparent, but do not exclude central hypogonadism; Kallmann syndrome is one cause, not a label for every boy whose testes remain small.
When hormone testing is indicated, interpret early-morning LH, FSH, and testosterone in the context of treatment timing and pediatric assay ranges. Low testosterone with low or inappropriately normal gonadotropins may occur in either self-limited delay or central hypogonadism. Elevated LH and FSH with low testosterone instead raises concern for primary gonadal dysfunction. These patterns help organize evaluation, but a single set of results may not settle the diagnosis.
Choose the next move without overcalling
If serial examination shows increasing testicular volume and pubertal changes continue off treatment, endogenous progression is more likely. Continue monitoring growth and puberty, while supporting the adolescent’s concerns about teasing or feeling out of step; psychosocial distress matters regardless of the eventual diagnosis.
If testicular volume remains prepubertal, reassess rather than reflexively repeating testosterone or assigning a permanent diagnosis. The next steps depend on age, examination, growth pattern, treatment timing, laboratory findings, and possible clues to functional suppression or pituitary, hypothalamic, or testicular disease. Pediatric endocrinology can guide targeted evaluation and decide whether ongoing pubertal induction is needed; the approach differs according to the cause.
Common traps
- Calling androgen effects proof of spontaneous puberty. A deeper voice or faster growth can be medication effects.
- Calling absent testicular growth “Kallmann syndrome.” Persistent lack of progression merits evaluation, but it does not identify a specific cause.
- Treating low LH and FSH as a complete answer. Results may overlap between self-limited delay and central hypogonadism.
- Promising a fixed outcome from family history or bone age. Both can inform counseling, but neither replaces follow-up or guarantees adult height.
Practical takeaways
- In boys, testicular enlargement—not pubic hair or voice change—is the key clinical marker of gonadarche.
- Testosterone-induced virilization shows androgen response, not necessarily activation of the boy’s own axis.
- Interpret serial testicular measurements and hormone results with the treatment timeline in view.
- Persistent lack of endogenous progression warrants reassessment, not an automatic diagnosis of Kallmann syndrome.
